A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection

Inclusion Criteria: * Chronic HCV infection at screening defined as: positive anti-HCV antibodies (Ab) at screening and HCV RNA \> 1,000 IU/mL at screening. * Plasma HIV-1 RNA \< 40 copies/mL during screening using Abbott RealTime HIV-1 assay. * On a stable qualifying HIV-1 antiretroviral therapy regimen. Exclusion Criteria: * Positive test result at screening for hepatitis B surface antigen. * Evidence of HCV genotype other than genotype 1 or genotype 4 during screening. * Receipt of any other investigational or commercially available anti-HCV agents (for example, telaprevir, boceprevir, simeprevir, daclatasvir and ledipasvir) with the exception of interferon (including pegylated-interferon alfa-2a or alfa-2b), sofosbuvir and ribavirin. * Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive ABT-450, ABT-267, ABT-333, ritonavir or ribavirin. * Chronic human immunodeficiency virus, type 2 (HIV-2) infection.